Efficacy and Safety of Tetrabenazine in Chorea

Phase 3CompletedNCT00219804

Prestwick Pharmaceuticals

Overview

The primary objective of this study was to establish the absolute reduction of chorea in participants with Huntington's disease(HD) treated with tetrabenazine or placebo

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

DOUBLE

Conditions

Huntington's Disease

Interventions

tetrabenazine or placeboDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years of age or older * suffer from manifest HD as confirmed by genetic testing * Meet chorea and total functional capacity scores on Unified Huntington's Disease Rating Scale * Meet criteria on Hamilton Depression Rating Scale, Unified Parkinson's Disease Rating Scale dysphagia and dysarthria scale * Independently ambulatory Exclusion Criteria * previous treatment with tetrabenazine * unstable or serious medical or psychiatric illness * concomitant use identified drugs * untreated depression * lack of caregiver

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.